In particular, the observation that patients whose tumours undergo a >50% reduction in contrast uptake or transfer constants in response to VEGF inhibitors usually attain stable or better disease, thus leading to the following questions regarding patient management: If we know that patients attaining 50% reduction in DCE-MRI parameters benefit from the drug, can we escalate the drug dose until this end point is reached? The gene discussed is VEGFA; the disease is neoplasm.